Patents by Inventor Daishiro Miura

Daishiro Miura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9073885
    Abstract: A compound represented by the following Formula (1) that is effective for the treatment of Paget's disease of bone or hypercalcemia or a medically acceptable solvate thereof; [wherein R1 refers to hydrogen atom, C1-C6 alkyl group optionally substituted with hydrogen group or C1-C6 alkoxy group optionally substituted with hydroxyl group, R2a and R2b refer to hydrogen atom, C1-C10 alkyl group optionally substituted with hydroxyl group, C6-C10 aryl group optionally substituted with hydroxyl group or C7-C12 aralkyl group optionally substituted with a hydroxyl group, or are combined to represent ethylene group. However, a compound in which R1 is a hydrogen atom or a methyl group and R2a and R2b are hydrogen atoms is excluded].
    Type: Grant
    Filed: January 29, 2004
    Date of Patent: July 7, 2015
    Assignee: Teijin Pharma Limited
    Inventors: Kazuya Takenouchi, Miyuki Anzai, Hiroshi Saito, Kazuhisa Okada, Seiichi Ishizuka, Daishiro Miura, Hiroaki Takayama, Atsushi Kittaka, Nozomi Saito, Toshie Fujishima
  • Patent number: 7300763
    Abstract: The objects of the present invention are to solve low test efficiency and low accuracy which are problems encountered in the conventional methods for testing myelotoxicity of a drug by observing smears. To this end, markers for discriminating and identifying hematopoietic stem cells and blood cells at various differentiation stages in bone marrow are identified. From this point of view, cell surface antigens are specified. Thus, it is found that the myelotoxicity of a drug can be evaluated with a high efficiency at a high accuracy by using flow cytometry to analyze for a change in the quantity of bone marrow-derived cells expressing the cell surface antigens after administration of the drug to an animal.
    Type: Grant
    Filed: June 8, 2001
    Date of Patent: November 27, 2007
    Assignee: Teijin Limited
    Inventors: Daishiro Miura, Shoko Ogata, Yukiya Koike
  • Publication number: 20060148768
    Abstract: A compound represented by the following Formula (1) that is effective for the treatment of Paget's disease of bone or hypercalcemia or a medically acceptable solvate thereof; [wherein R1 refers to hydrogen atom, C1-C6 alkyl group optionally substituted with hydrogen group or C1-C6 alkoxy group optionally substituted with hydroxyl group, R2a and R2b refer to hydrogen atom, C1-C10 alkyl group optionally substituted with hydroxyl group, C6-C10 aryl group optionally substituted with hydroxyl group or C7-C12 aralkyl group optionally substituted with a hydroxyl group, or are combined to represent ethylene group. However, a compound in which R1 is a hydrogen atom or a methyl group and R2a and R2b are hydrogen atoms is excluded].
    Type: Application
    Filed: January 29, 2004
    Publication date: July 6, 2006
    Inventors: Kazuya Takenouchi, Miyuki Anzai, Hiroshi Saito, Kazuhisa Okada, Seiichi Ishizuka, Daishiro Miura, Hiroaki Takayama, Atsushi Kittaka, Nozomi Saito, Toshie Fujishima
  • Publication number: 20050101574
    Abstract: An agent for suppressing the production of parathyroid hormone and a remedy for hyperparathyroidism containing a vitamin D3 derivative described by the following general formula (1) [in the formula, m is an integer of from 1 to 3, q is an integer of from 0 to 3, r is an integer of from 0 to 3 and X is carbon atom or oxygen atom, provided that 1?q+r?3] as an active ingredient.
    Type: Application
    Filed: August 29, 2001
    Publication date: May 12, 2005
    Inventors: Seiichi Ishizuka, Daishiro Miura, Kenji Manabe, Qingzhi Gao, Ryo Sogawa, Kazuya Takenouchi
  • Publication number: 20050101575
    Abstract: A vitamin D3 derivative expressed by the following general formula (1) [wherein, R is a hydrogen atom or a methyl group, and A is a single bond, —CH2—, —CH?CH—, —CH2—CH?CH—, —CH?CH—CH?CH—, —C?C— or —CH2—C?C—; and a compound in which R is an hydrogen atom, A is —CH2—, the steric configuration at the 1-position is (S)-configuration, and the steric configuration at the 3-position is (R)-configuration is excluded] or a pharmaceutically permissible solvate thereof. The compound can be an effective ingredient of a treating agent for osteoporosis, malignant tumor, psoriasis, hyperparathyroidism, an inflammatory respiratory disease, rheumatoid arthritis, growth onset type diabetes mellitus, hypertension, alopecia, acne, dermatitis, hypercalcemia or Paget's disease of bone.
    Type: Application
    Filed: February 19, 2003
    Publication date: May 12, 2005
    Inventors: Karuya Takenouchi, Miyuki Anzai, Kenji Manabe, Seiichi Ishizuka, Daishiro Miura
  • Publication number: 20040018985
    Abstract: A glutathione derivative having a dramatically enhanced hematopoiesis promoting effect in the living body, said derivative being represented by the formula (I): 1
    Type: Application
    Filed: July 21, 2003
    Publication date: January 29, 2004
    Applicant: TEIJIN LIMITED
    Inventors: Kiyoyuki Sakon, Yoshimitsu Naniwa, Mitsuru Kobayashi, Daishiro Miura, Hiroshi Imai, Atsushi Imaizumi
  • Patent number: 6627732
    Abstract: The present invention provides a glutathione derivative having a dramatically enhanced hematopoiesis promoting effect in the living body represented by the formula (I): where A represents H or a C1-C20 acyl group; R1 represents a C1-C26 alkyl group or a C3-C26 alkenyl group; and R2 represents H, a C1-C26 alkyl group or a C3-C26 alkyl group, with the proviso that compounds are excluded in which R1 is a C1-C10 alkyl group or a C3-C10 alkenyl group, and simultaneously R2 is H, a C1-C10 alkyl group or a C3-C10 alkenyl group. The present invention also provides a salt of the glutathione derivative, or a colloidal composition that enables the safe and effective development of the effects of the glutathione derivative in the living body.
    Type: Grant
    Filed: October 16, 2000
    Date of Patent: September 30, 2003
    Assignee: Teijin Limited
    Inventors: Kiyoyuki Sakon, Yoshimitsu Naniwa, Mitsuru Kobayashi, Daishiro Miura, Hiroshi Imai, Atsushi Imaizumi
  • Publication number: 20030148405
    Abstract: The subjects of the present invention are to solve low test efficiency and low accuracy which are problems encountering in the conventional methods for testing myelotoxicity by observing smears.
    Type: Application
    Filed: December 9, 2002
    Publication date: August 7, 2003
    Inventors: Daishiro Miura, Shoko Ogata, Yukiya Koike